COMPANY

BioMarck Pharmaceuticals, Ltd.

BioMarck Pharmaceuticals, Ltd. is listed on ClinicalTrials.gov as the lead sponsor of 3 studies; the most recently updated is “Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS” (Phase 2, completed), in Respiratory Distress Syndrome, Adult. From public records Source · Oct 12, 2026

Keywords: Adult Respiratory Distress Syndrome Non Small Cell Lung Cancer Stage IIIB COPD Chronic Obstructive Pulmonary Disease

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Feb 1, 2018 Trial start Phase 2: A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer source ↗
Aug 5, 2017 Trial start Phase 2: Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS source ↗
2008-06 Trial start Phase 2: Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT03202394	Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS	Phase 2	Completed	Aug 5, 2017	Mar 30, 2020 (actual)
NCT03472053	A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer	Phase 2	Completed	Feb 1, 2018	Dec 30, 2019 (actual)
NCT00648245	Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD	Phase 2	Completed	2008-06	2010-07 (actual)